A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Doses of AL003 in Healthy Participants and in Participants with Mild to Moderate Alzheimer's Disease

  • O'Brien, Terence (Primary Chief Investigator (PCI))
  • Burn, Katherine (Project Manager)

Project: Research

Project Details

Effective start/end date7/05/2031/12/20


  • Alzheimer's disease
  • Clinical trial